Medable vs Claude
Side-by-side comparison of AI visibility scores, market position, and capabilities
Medable raised $304M to build the leading decentralized clinical trial (DCT) platform, enabling remote patient participation, eConsent, and wearable data integration for pharmaceutical trials.
About
Medable provides the technology infrastructure for decentralized clinical trials (DCTs) — enabling pharmaceutical companies to conduct trials where patients participate from home rather than traveling to research sites. The platform covers the full DCT workflow: electronic informed consent (eConsent), remote patient monitoring via wearables, telemedicine visits, electronic clinical outcome assessments (eCOA), and direct-to-patient drug delivery coordination.
Claude 3.5 Sonnet topped coding and reasoning benchmarks in 2024; Claude 3.7 Sonnet with extended thinking launched in February 2025 as the leading model for complex professional tasks.
About
Claude is Anthropic's AI assistant, first released publicly in March 2023 and now one of the top three most-used AI assistants globally. Claude 3.5 Sonnet (June 2024) set benchmarks for coding, analysis, and instruction-following that led many developers and enterprises to migrate from GPT-4. Claude is available via claude.ai (free and Pro tiers at $20/month) and through the Anthropic API powering thousands of enterprise applications.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.